Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism

• STRAUS SM, BLEUMINK GS, DIELEMAN JP et al.: Antipsychotics and the risk of sudden cardiac death. Arch. Intern. Med. (2004) 164(12):1293-1297.
   PubMed Web of Science ®Google Scholar
• GLASSMAN AH, BIGGER JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry. (2001) 158(11):1774-1782.
   PubMed Web of Science ®Google Scholar
• REILLY JG, AYIS SA, FERRIER IN, JONES SJ, THOMAS SH: Thioridazine and sudden unexplained death in psychiatric in-patients. Br. J. Psychiatry (2002) 180:515-522.
   PubMed Web of Science ®Google Scholar
• HARRISON MO, KRISHNAN KR: Antipsychotic medications and sudden cardiac death. Psychopharmacol. Bull. (2002) 36(3):91-99.
   PubMedGoogle Scholar
• LIN CH, CHEN MC, WANG SY, LIN CY: Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. J. Formos. Med. Assoc. (2004) 103(6):437-441.
   PubMed Web of Science ®Google Scholar
• ZAREBA W, LIN DA: Antipsychotic drugs and QT interval prolongation. Psychiatr. Q. (2003) 74(3):291-306.
   PubMed Web of Science ®Google Scholar
• TITIER K, CANAL M, DERIDET E et al.: Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol. Appl. Pharmacol. (2004) 199(1):52-60.
   PubMed Web of Science ®Google Scholar
• KONGSAMUT S, KANG J, CHEN XL, ROEHR J, RAMPE D: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. (2002) 450(1):37-41.
   PubMed Web of Science ®Google Scholar
• GLUAIS P, BASTIDE M, CARON J, ADAMANTIDIS M: Risperidone prolongs cardiac action potential through reduction of K(+) currents in rabbit myocytes. Eur. J. Pharmacol. (2002) 444(3):123-132.
   PubMed Web of Science ®Google Scholar
• MAGYAR J, BÁNYÁSZ T, BAGI Z et al.: Electrophysiological effects of risperidone in mammalian cardiac cells. Naunyn Schmiedebergs Arch. Pharmacol. (2002) 366(4):350-356.
   PubMed Web of Science ®Google Scholar
• SHADER RI, GREENBLATT DJ: More on potassium, the heart, and antipsychotic agents. J. Clin. Psychopharmacol. (1999) 19(3):201-202.
   PubMed Web of Science ®Google Scholar
• WELCH R, CHUE P: Antipsychotic agents and QT changes. J. Psychiatry Neurosci. (2000) 25(2):154-160.
   PubMed Web of Science ®Google Scholar
• REDFERN WS, CARLSSON L, DAVIS AS et al.: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. (2003) 58(1):32-45.
   PubMed Web of Science ®Google Scholar
• HONDEGHEM LM: Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J. Cardiovasc. Electrophysiol. (2006) 17(3):337-340.
   PubMed Web of Science ®Google Scholar
• HONDEGHEM LM, CARLSSON L, DUKER G: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation (2001) 103(15):2004-2013.
   PubMed Web of Science ®Google Scholar
• RETTENBACHER MA, EDER-ISCHIA U, BADER A et al.: QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. J. Clin. Psychopharmacol. (2005) 25(3):206-210.
   PubMed Web of Science ®Google Scholar
• COMMITTEE ON SAFETY OF MEDICINES: QT interval prolongation with antipsychotics. Curr. Probl. Pharmacovigilance (2001) 27:4.
   Google Scholar
• BUCKLEY NA, WHYTE IM, DAWSON AH: Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J. Toxicol. Clin. Toxicol. (1995) 33(3):199-204.
   PubMed Web of Science ®Google Scholar
• DALLAIRE S: Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval. CMAJ (2001) 164(1):91-95.
   PubMedGoogle Scholar
• STRACHAN EM, KELLY CA, BATEMAN DN: Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning. Eur. J. Clin. Pharmacol. (2004) 60(8):541-545.
   PubMed Web of Science ®Google Scholar
• HALE PW JR, POKLIS A: Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol. Appl. Pharmacol. (1986) 86(1):44-55.
   PubMed Web of Science ®Google Scholar
• HAVERKAMP W, BREITHARDT G, CAMM AJ et al.: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur. Heart J. (2000) 21(15):1216-1231. Simultaneously published in: Cardiovasc. Res. (2000) 47(2):219-233.
   Google Scholar
• TRISTANI-FIROUZI M, CHEN J, MITCHESON JS, SANGUINETTI MC: Molecular biology of K(+) channels and their role in cardiac arrhythmias. Am. J. Med. (2001) 110(1):50-59.
   PubMed Web of Science ®Google Scholar
• DROLET B, ZHANG S, DESCHENES D et al.: Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Electrophysiol. (1999) 10(12):1597-1604.
   PubMed Web of Science ®Google Scholar
• REILLY JG, AYIS SA, FERRIER IN, JONES SJ, THOMAS SH: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet (2000) 355(9209):1048-1052.
   PubMed Web of Science ®Google Scholar
• DILLENKOFFER RL, GALLANT DM, PHILLIPS JH: Electrocardiographic evaluation of mesoridazine (Serentil). Curr. Ther. Res. Clin. Exp. (1972) 14(2):71-72.
   PubMed Web of Science ®Google Scholar
• HARTIGAN-GO K, BATEMAN DN, NYBERG G, MARTENSSON E, THOMAS SH: Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin. Pharmacol. Ther. (1996) 60(5):543-553.
   PubMed Web of Science ®Google Scholar
• LLERENA A, BERECZ R, DE LA RUBIA A, DORADO P: QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J. Psychopharmacol. (2002) 16(4):361-364.
   PubMed Web of Science ®Google Scholar
• LLERENA A, BERECZ R, DE LA RUBIA A, NORBERTO MJ, BENITEZ J: Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther. Drug Monit. (2000) 22(4):397-401.
   PubMed Web of Science ®Google Scholar
• LLERENA A, BERECZ R, DE LA RUBIA A, FERNANDEZ-SALGUERO P, DORADO P: Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. (2001) 23(6):616-620.
   PubMed Web of Science ®Google Scholar
• BERECZ R, DE LA RUBIA A, DORADO P, FERNANDEZ-SALGUERO P, DAHL ML, LLERENA A: Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur. J. Clin. Pharmacol. (2003) 59(1):45-50.
   PubMed Web of Science ®Google Scholar
• FULOP G, PHILLIPS RA, SHAPIRO AK, GOMES JA, SHAPIRO E, NORDLIE JW: ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am. J. Psychiatry (1987) 144(5):673-675.
   PubMed Web of Science ®Google Scholar
• CZEKALLA J, KOLLACK-WALKER S, BEASLEY C: Cardiac safety of olanzapine: comparison with other atypical and atypical antipsychotics. J. Clin. Psychiatry (2001) 62(Suppl. 2):35-40.
   PubMed Web of Science ®Google Scholar
• HATTA K, TAKAHASHI T, NAKAMURA H et al.: The association between intravenous haloperidol and prolonged QT interval. J. Clin. Psychopharmacol. (2001) 21(3):257-261.
   PubMed Web of Science ®Google Scholar
• KRIWISKY M, PERRY GY, TARCHITSKY D, GUTMAN Y, KISHON Y: Haloperidol-induced torsades de pointes. Chest (1990) 98(2):482-484.
   PubMed Web of Science ®Google Scholar
• DI SALVO TG, O’GARA PT: Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin. Cardiol. (1995) 18(5):285-290.
   PubMed Web of Science ®Google Scholar
• SHARMA ND, ROSMAN HS, PADHI ID, TISDALE JE: Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am. J. Cardiol. (1998) 81(2):238-240.
   PubMed Web of Science ®Google Scholar
• O’BRIEN JM, ROCKWOOD RP, SUH KI: Haloperidol-induced torsade de pointes. Ann. Pharmacother. (1999) 33(10):1046-1050.
   PubMed Web of Science ®Google Scholar
• REMIJNSE PL, EECKHOUT AM, VAN GULDENER C: Sudden death following a single oral administration of haloperidol. Ned. Tijdschr. Geneeskd. (2002) 146(16):768-771.
   PubMedGoogle Scholar
• HASSABALLA HA, BALK RA: Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use. Expert. Opin. Drug. Saf. (2003) 2(6):543-547.
   PubMedGoogle Scholar
• AUNSHOLT NA: Prolonged Q-T interval and hypokalemia caused by haloperidol. Acta Psychiatr. Scand. (1989) 79(4):411-412.
   PubMed Web of Science ®Google Scholar
• HENDERSON RA, LANE S, HENRY JA: Life-threatening ventricular arrhythmia (Torsade de Pointes) after haloperidol overdose. Human Exp. Toxicol. (1991) 10(1):59-62.
   PubMed Web of Science ®Google Scholar
• METZGER E, FRIEDMAN R: Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J. Clin. Psychopharmacol. (1993) 13(2):128-132.
   PubMed Web of Science ®Google Scholar
• YOSHIDA I, SAKAGUCHI Y, MATSUISHI T et al.: Acute accidental overdosage of haloperidol in children. Acta Paediatr. (1993) 82(10):877-880.
   PubMed Web of Science ®Google Scholar
• TESAR GE, MURRAY GB, CASSEM NH: Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. J Clin Psychopharmacol. (1985) 5(6):344-347.
   PubMed Web of Science ®Google Scholar
• GUY JM, ANDRE-FOUET X, PORTE J, BERTRAND M, LAMAUD M, VERNEYRE H: Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol. Ann. Cardiol. Angeiol. (1991) 40(9):541-545.
   PubMed Web of Science ®Google Scholar
• LISCHKE V, BEHNE M, DOELKEN P, SCHLEDT U, PROBST S, VETTERMANN J: Droperidol causes a dose-dependent prolongation of the QT interval. Anesth. Analg. (1994) 79(5):983-986.
   PubMed Web of Science ®Google Scholar
• VORMBERGE T, HOFFMANN M, HIMMEL H: Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. J. Pharmacol. Toxicol. Methods (2006) 54(2):130-140.
   PubMedGoogle Scholar
• WHITE PF, SONG D, ABRAO J, KLEIN KW, NAVARETTE B: Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology (2005) 102(6):1101-1105.
   PubMed Web of Science ®Google Scholar
• MERRILL DB, DEC GW, GOFF DC: Adverse cardiac effects associated with clozapine. J. Clin. Psychopharmacol. (2005) 25(1):32-41.
   PubMed Web of Science ®Google Scholar
• KANG UG, KWON JS, AHN YM et al.: Electrocardiographic abnormalities in patients treated with clozapine. J. Clin. Psychiatry (2000) 61(6):441-446.
   PubMed Web of Science ®Google Scholar
• ALEXOPOULOS GS, STREIM J, CARPENTER D, DOCHERTY JP: Expert consensus panel for using antipsychotic drugs in older patients. J. Clin. Psychiatry. (2004) 65(Suppl. 2):5-99.
   PubMed Web of Science ®Google Scholar
• DROLET B, YANG T, DALEAU P, RODEN DM, TURGEON J: Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Pharmacol. (2003) 41(6):934-937.
   PubMed Web of Science ®Google Scholar
• BROWN K, LEVY H, BRENNER C, LEFFLER S, HAMBURG EL: Overdose of risperidone. Ann. Emerg. Med. (1993) 22(12):1908-1910.
   PubMed Web of Science ®Google Scholar
• LO VECCHIO F, HAMILTON RJ, HOFFMAN RJ: Risperidone overdose. Am. J. Emerg. Med. (1996) 14(1):95-96.
   PubMed Web of Science ®Google Scholar
• KOPALA LC, DAY C, DILLMAN B, GARDNER D: A case of risperidone overdose in early schizophrenia: a review of potential complications. J. Psychiatry Neurosci. (1998) 23(5):305-308.
   PubMed Web of Science ®Google Scholar
• RAVIN DS, LEVENSON JW: Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother. (1997) 31(7-8):867-870.
   PubMed Web of Science ®Google Scholar
• ZARATE CA JR, BALDESSARINI RJ, SIEGEL AJ et al.: Risperidone in the elderly: a pharmacoepidemiologic study. J. Clin. Psychiatry (1997) 58(7):311-317.
   PubMed Web of Science ®Google Scholar
• POSEY DJ, WALSH KH, WILSON GA, MCDOUGLE CJ: Risperidone in the treatment of two very young children with autism. J. Child. Adolesc. Psychopharmacol. (1999) 9(4):273-276.
   PubMed Web of Science ®Google Scholar
• RAVINA T, RAVINA P, GUTIERREZ J: Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I. Int. J. Cardiol. (2006) (In Press).
   Google Scholar
• SMALL JG, HIRSCH SR, ARVANITIS LA, MILLER BG, LINK CG: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry (1997) 54(6):549-557.
   PubMed Web of Science ®Google Scholar
• MCMANUS DQ, ARVANITIS LA, KOWALCYK BB: Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J. Clin. Psychiatry (1999) 60(5):292-298.
   PubMed Web of Science ®Google Scholar
• VIEWEG WV, SCHNEIDER RK, WOOD MA: Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr. Scand. (2005) 112(4):318-322.
   PubMed Web of Science ®Google Scholar
• HUSTEY FM: Acute quetiapine poisoning. J. Emerg. Med. (1999) 17(6):995-997.
   PubMed Web of Science ®Google Scholar
• GAJWANI P, POZUELO L, TESAR GE: QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics (2000) 41(1):63-65.
   PubMed Web of Science ®Google Scholar
• BEELEN AP, YEO KT, LEWIS LD: Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum. Exp. Toxicol. (2001) 20(4):215-219.
   PubMed Web of Science ®Google Scholar
• BALIT CR, ISBISTER GK, HACKETT LP, WHYTE IM: Quetiapine poisoning: a case series. Ann. Emerg. Med. (2003) 42(6):751-758.
   PubMed Web of Science ®Google Scholar
• KURTH J, MAGUIRE G: Pediatric case report of quetiapine overdose and QTc prolongation. Ann. Clin. Psychiatry (2004) 16(4):229-231.
   PubMedGoogle Scholar
• STRACHAN PM, BENOFF BA: Mental status change, myoclonus, electrocardiographic changes, and acute respiratory distress syndrome induced by quetiapine overdose. Pharmacotherapy (2006) 26(4):578-582.
   PubMed Web of Science ®Google Scholar
• MINOV C: Risk of QTc prolongation due to combination of ziprasidone and quetiapine. Psychiatr. Prax. (2004) 31(Suppl. 1):142-144.
   Google Scholar
• PRECOURT A, DUNEWICZ M, GREGOIRE G, WILLIAMSON DR: Multiple complications and withdrawal syndrome associated with quetiapine/venlafaxine intoxication. Ann. Pharmacother. (2005) 39(1):153-156.
   PubMed Web of Science ®Google Scholar
• BLAIR J, SCAHILL L, STATE M, MARTIN A: Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J. Am. Acad. Child. Adolesc. Psychiatry (2005) 44(1):73-79.
   PubMed Web of Science ®Google Scholar
• CENTORRINO F, MACLEAN E, SALVATORE P et al.: Ziprasidone: first year experience in a hospital setting. J. Psychiatr. Pract. (2004) 10(6):361-367.
   PubMed Web of Science ®Google Scholar
• HEINRICH TW, BIBLO LA, SCHNEIDER J: Torsades de pointes associated with ziprasidone. Psychosomatics (2006) 47(3):264-268.
   PubMed Web of Science ®Google Scholar
• SU Z, CHEN J, MARTIN RL et al.: Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem. Pharmacol. (2006) 71(3):278-286.
   PubMed Web of Science ®Google Scholar
• WARD DI: Two cases of amisulpride overdose: A cause for prolonged QT syndrome. Emerg. Med. Australas. (2005) 17(3):274-276.
   PubMedGoogle Scholar
• PEDROSA GIL F, GROHMANN R, RUTHER E: Asymptomatic bradycardia associated with amisulpride. Pharmacopsychiatry (2001) 34(6):259-261.
   PubMed Web of Science ®Google Scholar
• COULOUVRAT C, DONDEY-NOUVEL LD: Safety of amisulpride (Solian®): a review of 11 clinical studies. Int. Clin. Psychopharmacol. (1999) 14(4):209-218.
   PubMed Web of Science ®Google Scholar
• HARRIGAN EP, MICELI JJ, ANZIANO R et al.: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. (2004) 24(1):62-69.
   PubMed Web of Science ®Google Scholar
• BERECZ R, KELLERMANN M, GLAUB T, DEGRELL I: Olanzapine intoxication. A case report. Psychiatr. Hung. (2000) 15:176-178.
   Google Scholar
• CRUMB W, LLORCA PM, LANCON C, THOMAS GP, GARAY RP, HAMEG A: Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. Eur. J. Pharmacol. (2006) 532(3):270-278.
   PubMed Web of Science ®Google Scholar
• KANE JM, TAMMINGA CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin. Investig. Drugs (1997) 6(11):1729-1741.
   PubMedGoogle Scholar
• LEWIS R, BAGNALL AM, LEITNER M: Sertindole for schizophrenia. Cochrane Database Syst. Rev. (2005) 20(3):CD001715.
   Google Scholar
• AZORIN JM, STRUB N, LOFT H: A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int. Clin. Psychopharmacol. (2006) 21(1):49-56.
   PubMed Web of Science ®Google Scholar
• WILTON LV, HEELEY EL, PICKERING RM, SHAKIR SA: Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J. Psychopharmacol. (2001) 15(2):120-126.
   PubMed Web of Science ®Google Scholar
• RAMPE D, MURAWSKY MK, GRAU J, LEWIS EW: The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J. Pharmacol. Exp. Ther. (1998) 286(2):788-793.
   PubMed Web of Science ®Google Scholar
• ZOTEPINE WORKSHOP: Clinical Appraisal of Zotepine in Psychiatric Therapy. Amsterdam, The Netherlands, October (2005).
   Google Scholar
• LLERENA A, DAHL ML, EKQVIST B, BERTILSSON L: Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit. (1992) 14(3):261-264.
   PubMed Web of Science ®Google Scholar
• LLERENA A, DE LA RUBIA A, BERECZ R, DORADO P: Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry (2004) 37(2):69-73.
   PubMed Web of Science ®Google Scholar
• BERECZ R, LLERENA A, DE LA RUBIA A et al.: Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry (2002) 35(6):231-234.
   PubMed Web of Science ®Google Scholar
• LLERENA A, BERECZ R, DORADO P, DE LA RUBIA A: QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J. Psychopharmacol. (2004) 18(2):189-193.
   PubMed Web of Science ®Google Scholar
• SOMEYA T, SHIMODA K, SUZUKI Y et al.: Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology (2003) 28(8):1501-1505.
   PubMed Web of Science ®Google Scholar
• LLERENA A, BERECZ R, DE LA RUBIA A, DORADO P: QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. Eur. J. Clin. Pharmacol. (2002) 58(3):223-224.
   PubMed Web of Science ®Google Scholar
• LLERENA A, EDMAN G, COBALEDA J, BENITEZ J, SCHALLING D, BERTILSSON L: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. (1993) 87(1):23-28.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.qtdrugs.org/medical-pros/drug-lists/drug-lists.htmThe University of Arizona Center for Education and Research on Therapeutics.
   Google Scholar
• http://www.fda.gov/medwatch/safety/2000/mellar.htmNovartis Pharmaceutical Corporation (2000).
   Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdfPsychopharmacological Drug Advisory Committee (PDAC). FDA (2000).
   Google Scholar